Inactivation of the p15 gene in children with acute lymphoblastic leukemia
Keywords:
Acute lymphoblastic leukemia, Lymphoblastic leukemia, Tumor suppressor gene, p15Abstract
CONTEXT: Tumor suppressor genes act on the control of cell cycle progression. In pediatric neoplasias, some of these genes may be considered to be markers for diagnosis or relapse, thus probably representing prognostic indicators. OBJECTIVE: To study the inactivation of the p15 gene in children with acute lymphoblastic leukemia. TYPE OF STUDY: Retrospective study. SETTING: Laboratory of Molecular Biology, Department of Pediatrics, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. PARTICIPANTS: Eighty-three children and adolescents with acute lymphoblastic leukemia were studied, with the examination of 83 bone marrow samples obtained at diagnosis, four obtained also during relapse, and two cerebrospinal fluid samples obtained from two cases of isolated relapse in the central nervous system. MAIN MEASUREMENTS: Homologous deletion of the p15 gene by multiplex polymerase chain reaction, and screening for point mutations by polymerase chain reaction/single-strand conformational polymorphism. RESULTS: Deletion of exon 2 of the p15 gene was observed in 15 children, including one case in which deletion was only verified during isolated central nervous system relapse. No case of exon 1 deletion, or that was suggestive of point mutations, was observed and no association between p15 gene inactivation and classic risk factors was established. CONCLUSION: According to the literature, inactivation of the p15 gene by deletion of exon 2 in acute lymphoblastic leukemia found in the population studied would be considered to be a molecular marker for diagnosis or relapse. However, no correlation between p15 gene deletion and clinical prognostic indicators was observed.
Downloads
References
Schüz J, Kaatsch P, Kaletsch U, Meinert R, Michaelis J. Asso- ciation of childhood cancer with factors related to pregnancy and birth. Int J Epidemiol 1999;28(4):631-9.
Stass SA, Mixson J. Oncogenes and tumor suppressor genes: thera- peutic implications. Clin Cancer Res 1997;3(12 Pt 2):2687-95.
Hunter T, Pines J. Cyclins and cancer II: Cyclin D and CDK inhibitors come of age. Cell 1994;79(4):573-82.
Hannon GJ, Beach D. p15INK4B is a potential effector of TGF- beta-induced cell cycle arrest. Nature 1994;371(6494):257-61.
Heyman M, Rasool O, Borgonovo Brandter L, et al. Prognos- tic importance of p15INK4B and p16INK4 gene inactivation in childhood acute lymphocytic leukemia. J Clin Oncol 1996;14(5):1512-20.
Batova A, Diccianni MB, Yu JC, et al. Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia. Cancer Res 1997;57(5):832-6.
Maloney KW, McGavran L, Odom LF, Hunger SP. Different patterns of homozygous p16INK4A and p15INK4B deletions in childhood acute lymphoblastic leukemias containing distinct E2A translocations. Leukemia 1998;12(9):1417-21.
Brandalise S, Odone V, Pereira W, et al. Treatment results of three consecutive Brazilian cooperative childhood ALL protocols: GBTLI-80, GBTLI-82 and -85. ALL Brazilian Group. Leukemia 1993;7:(Suppl 2):S142-5.
Saiki RK, Gelfand DH, Stoffel S, et al. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1988;239(4839):487-91.
Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T. De- tection of polymorphisms of human DNA by gel electrophore- sis as single-strand conformation polymorphisms. Proc Natl Acad Sci USA 1989;86(8):2766-70.
Sambrook J, Fritsch EF, Maniatis J. Molecular Cloning: A Labo- ratory Manual. 2nd ed. Philadelphia: Cold Spring Harbor Labo- ratory Press; 1989.
- Rasool O, Heyman M, Brandter LB, et al. p15INK4B and p16INK4 gene inactivation in acute lymphocytic leukemia. Blood 1995;85(12):3431-6.
Hebert J, Cayuela JM, Berkeley J, Sigaux F. Candidate tumor suppressor genes MTS1 (p16INK4A) and MTS2 (p15INK4B) display frequent homozygous deletions in primary cells from T- but not from B-cell lineage acute lymphoblastic leukemias. Blood 1994;84(12):4038-44.
Otsuki T, Clark HM, Wellmann A, Jaffe ES, Raffeld M. In- volvement of CDKN2 (p16INK4A/MTS1) and p15INK4B/ MTS2 in human leukemias and lymphomas. Cancer Res 1995;55(7):1436-40.
Okuda T, Shurtleff SA, Valentine MB, et al. Frequent deletion of p16INK4a/MTS1 and p15INK4b/MTS2 in pediatric acute lymphoblastic leukemia. Blood 1995;85(9):2321-30.
Takeuchi S, Bartram CR, Seriu T, et al. Analysis of a family of cyclin-dependent kinase inhibitors: p15/MTS2/INK4B, p16/ MTS1/INK4A, and p18 genes in acute lymphoblastic leukemia of childhood. Blood 1995;86(2):755-60.
Iravani M, Dhat R, Price CM. Methylation of the multi tumor suppressor gene-2 (MTS2, CDKN1, p15INK4B) in childhood acute lymphoblastic leukemia. Oncogene 1997;15(21):2609-14.
Hangaishi A, Ogawa S, Imamura N, et al. Inactivation of mul- tiple tumor-suppressor genes involved in negative regulation of the cell cycle, MTS1/p16INK4A/CDKN2/, MTS2/p15INK4B, p53, and Rb genes in primary lymphoid malignancies. Blood 1996;87(12):4949-58.
Thullberg M, Bartkova J, Khan S, et al. Distinct versus redun- dant properties among members of the INK4 family of cyclin- dependent kinase inhibitors. FEBS Lett 2000;470(2):161-6.
Guo SX, Taki T, Ohnishi H, et al. Hypermethylation of p16 and p15 genes and RB protein expression in acute leukemia. Leuk Res 2000;24(1):39-46.
Bringold F, Serrano M. Tumor suppressors and oncogenes in cellular senescence. Exp Gerontol 2000;35(3):317-29.
Fink JR, LeBien TW. Novel expression of cyclin-dependent ki- nase inhibitors in human B-cell precursors. Exp Hematol 2001;29(4):490-8.
